Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company pioneering receptor-targeted therapies for metabolic and endocrine disorders. This page serves as the definitive source for all official updates and analysis-worthy developments related to the company’s innovative pipeline.
Investors and industry observers will find timely, verified information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases on key programs like the thyroid receptor agonist VK2809 for NASH, dual GLP-1/GIP agonist VK2735 for obesity, and rare disease candidate VK0214 – all developed through Viking’s receptor-specific therapeutic approach.
Content is organized to highlight material events including Phase 1-3 trial results, FDA communications, patent developments, and peer-reviewed research publications. Each update is contextualized within Viking’s broader mission to address unmet needs in metabolic health through precision pharmacology.
For consistent monitoring of Viking’s advancements in liver disease and endocrine disorder treatments, bookmark this page and revisit for authoritative reporting on trial data disclosures and corporate announcements. All content adheres to strict journalistic standards for accuracy and regulatory compliance.
Viking Therapeutics (NASDAQ: VKTX) announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an oral tablet formulation targeting obesity treatment. The study achieved both primary and secondary endpoints, demonstrating significant weight loss benefits.
Key highlights include: Up to 12.2% (26.6 lbs) mean weight loss in treated patients compared to 1.3% (2.9 lbs) for placebo after 13 weeks. The trial showed impressive efficacy with up to 97% of subjects achieving ≥5% weight loss and up to 80% achieving ≥10% weight loss. The drug demonstrated a favorable safety profile with 99% of GI-related adverse events being mild or moderate.
An exploratory maintenance dosing cohort showed promising results, suggesting effective weight maintenance may be achieved at lower doses (30mg) after initial treatment with higher doses.
Viking Therapeutics (NASDAQ:VKTX) reported Q2 2025 financial results and pipeline updates. The company has initiated the Phase 3 VANQUISH registration trials for VK2735 in obesity, following successful Phase 2 results showing up to 14.7% weight reduction. The VANQUISH program includes two studies targeting approximately 5,600 patients total.
Viking completed enrollment in the Phase 2 VENTURE-Oral dosing trial for their oral obesity treatment, with results expected in 2H25. The company is also advancing its amylin agonist program with an IND planned for Q4 2025. Financial results showed a net loss of $65.6 million for Q2, with a strong cash position of $808 million as of June 30, 2025.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, will release its Q2 2025 financial results on Wednesday, July 23, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide corporate updates. Investors can join via phone or watch the webcast through Viking's website. A replay will be available until July 30, 2025, and the webcast recording will be accessible for 30 days.
Viking Therapeutics (NASDAQ: VKTX) has launched its Phase 3 VANQUISH clinical program for VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The program consists of two major studies: VANQUISH-1, targeting 4,500 obese adults, and VANQUISH-2, targeting 1,100 obese/overweight adults with type 2 diabetes.
The 78-week trials will evaluate three dosing arms (7.5mg, 12.5mg, 17.5mg) against placebo, with the primary endpoint measuring body weight change. The announcement follows successful Phase 2 VENTURE study results, where VK2735 achieved up to 14.7% body weight reduction and demonstrated favorable safety profiles with mostly mild to moderate adverse events.
Viking also plans to initiate a study for monthly maintenance dosing and expects to report Phase 2 results for the oral formulation in late 2025.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has announced its participation in four major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference (June 3-5) in Chicago - Including corporate presentation and fireside chat
- Jefferies Global Healthcare Conference (June 3-5) in New York - Featuring corporate presentation with webcast availability
- Goldman Sachs Global Healthcare Conference (June 9-11) in Miami
- Scotiabank Healthcare Canadian Investor Day (June 17) in Toronto
The company will conduct one-on-one meetings at all events, with a live webcast available for the Jefferies presentation through Viking's website.
Viking Therapeutics (VKTX) has reported its Q1 2025 financial results and provided key updates on its clinical pipeline. The company ended the quarter with a strong cash position of $852 million, down from $903 million in December 2024. The quarter saw a net loss of $45.6 million ($0.41 per share), compared to $27.4 million ($0.26 per share) in Q1 2024.
Key developments include:
- Phase 3 trials for subcutaneous VK2735 obesity treatment expected to begin in Q2 2025
- Completion of enrollment in Phase 2 VENTURE-Oral Dosing trial, with data expected in 2H 2025
- New manufacturing agreement with CordenPharma for VK2735 commercialization
- Advancement of novel amylin agonist program with IND filing planned for 2H 2025
R&D expenses increased to $41.4 million from $24.1 million year-over-year, while G&A expenses rose to $14.1 million from $10.0 million.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has scheduled its first quarter 2025 financial results release for April 23, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss financial results and corporate updates. Participants can join via phone (U.S.: 844-850-0543; International: 412-317-5199) or through the company's website. A replay will be available until April 30, 2025, using access code #8779272.
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint focuses on body weight change after 13 weeks, with results expected in 2H25. Previous Phase 1 results showed promising outcomes, with weight reductions up to 8.2% after 28 days and up to 8.3% at follow-up. The drug demonstrated favorable safety profile with 99% of adverse events being mild or moderate.
Notably, Viking is also developing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in 1H25.
Viking Therapeutics (VKTX) has entered a multi-year strategic partnership with CordenPharma for the development and manufacturing of its GLP-1 drug candidate VK2735. The partnership encompasses the full supply chain from drug substance to drug product for both subcutaneous and oral peptide formulations.
CordenPharma will provide large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance, along with fill-finish services for the subcutaneous formulation and oral solid dosage manufacturing. The agreement leverages CordenPharma's global network of manufacturing facilities, featuring built-in redundancy through multiple drug substance sites to ensure uninterrupted supply throughout the product lifecycle.
Viking Therapeutics (NASDAQ: VKTX) has secured a major manufacturing agreement with CordenPharma for its VK2735 obesity treatment program. The multi-year contract ensures dedicated production capacity for both subcutaneous and oral formulations to support potential multi-billion-dollar annual product sales.
The agreement includes:
- Annual production capacity for multiple metric tons of VK2735 API
- 100 million autoinjectors and 100 million vial/syringe products annually
- Over 1 billion oral tablets manufacturing capacity per year
Viking will make prepayments totaling $150 million between 2025-2028, which will be credited against future orders. The company maintains all global rights to VK2735 and expects standard pharmaceutical product margins. Currently, VK2735 is in Phase 2 VENTURE-Oral Dosing Trial, with Phase 3 development for the subcutaneous formulation planned for Q2 2025.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
